6533b827fe1ef96bd128660d

RESEARCH PRODUCT

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

Vitale FrancescoStefano PizzoGiuseppe CalamusaDario GenoveseCasuccio AlessandraDonatella FerraroEmanuele AmodioFloriana BonuraGiuseppina CapraGiovanni M. GiammancoSimona De Grazia

subject

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccine

description

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

yearjournalcountryeditionlanguage
2021-07-01Vaccines
10.3390/vaccines9070714http://europepmc.org/articles/PMC8309986